Sernova (SVA) Stock Price, News & Analysis

Company Overview

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on Type 1 diabetes and thyroid disorders.

Key Stats

• Today's Range: C$0.17 to C$0.18
• 50-Day Range: C$0.16 to C$0.22
• 52-Week Range: C$0.15 to C$0.40
• Volume: 108,380 shs
• Average Volume: 151,773 shs
• Market Capitalization: C$57.20 million
• P/E Ratio: N/A
• Dividend Yield: 7.86%
• Price Target: C$2.00
• Consensus Rating: Buy

SVA Stock Analysis - Frequently Asked Questions

How have SVA shares performed this year?

Sernova's stock was trading at C$0.23 at the start of the year. Since then, SVA stock has decreased by 24.4% and is now trading at C$0.17.
View the best growth stocks for 2025 here.

How do I buy shares of Sernova?

Shares of SVA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Sernova own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sernova investors own include ARC Resources (ARX), Meta Platforms (META), Newron Pharmaceuticals (NWPHF), Sernova (SEOVF), AMC Entertainment (AMC), Advanced Micro Devices (AMD) and CloudMD Software & Services (DOC).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:SVA
• CIK: N/A
• Web: www.sinovacbio.com
• Phone: 861082890088
• Fax: N/A
• Employees: 1,959
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$2.00
• High Stock Price Target: C$2.50
• Low Stock Price Target: C$1.50
• Potential Upside/Downside: +1,076.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$35.70 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 473.85%
• Return on Assets: -119.26%

Debt

• Debt-to-Equity Ratio: -4.40
• Current Ratio: 0.32
• Quick Ratio: 18.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.03 per share
• Price / Cash Flow: 6.15
• Book Value: C($0.04) per share
• Price / Book: -3.98

Miscellaneous

• Outstanding Shares: 336,496,829
• Free Float: N/A
• Market Cap: C$57.20 million
• Optionable: Not Optionable
• Beta: 1.35